Keywords:
tuberculosis, treatment, drugs, resistance, standardization.References
Ahuja, S.D. Collaborative Group for Meta-Analysis of Individual Patient Data in MDRTB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data metaanalysis of 9,153 patients / S.D. Ahuja, D. Ashkin, M. Avendano [et al.] // PLoS Med. - 2012. - Vol. 9: e1001300.
Aung, K.J. Successful ’9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients / K.J. Aung, A. Van Deun, E. Declercq [et al.] // Int. J. Tuberc. Lung Dis. - 2014. - Vol.18. - P.1180–1187.
Bastos, M.L. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis / M.L. Bastos, Z. Lan, D. Menzies // Eur. Respir. J. - 2017. - Vol. 49. - P.1600803.
Borisov, S.E. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: a multicentre study / S.E. Borisov, K. Dheda, M. Enwerem [et al.] // Eur. Respir. J. - 2017. - Vol.49. - P.1700387.
Conradie, F. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid / F. Conradie, A. Diacon, P. Howell [et al.] // Int. J. Tuberc. Lung. Dis. - 2018. - Vol. 22, Suppl. 2. - P.69.
Dalcolmo, M. Effectiveness and safety of clofazimine in multidrugresistant tuberculosis: a nationwide report from Brazil / M. Dalcolmo, R. Gayoso, G.Sotgiu [et al.] // Eur.Respir. J.-2017.-Vol.49 (3)
Dheda, K. Recent controversies about MDR and XDR-TB: global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? / K. Dheda, H. Cox, A. Esmail [et al.] // Respirology. - 2018. - Vol. 23. - P.36–45.
Diacon, A.H. Multidrug-resistant tuberculosis and culture conversion with bedaquiline / A.H. Diacon, A. Pym, M.P. Grobusch [et al.] // N. Engl. J. Med. - 2014. - Vol.371. - P. 723–732.
Dooley, K.E. World Health Organization group 5 drugs for the treatment of drugresistant tuberculosis: unclear efficacy or untapped potential? / K.E. Dooley, E.A. Obuku, N. Durakovic [et al.] // J In-fect Dis. - 2013. - Vol.207(9).- P.1352–1358.
Falzon, D. World Health Organization treatment guidelines for drugresistant tuberculosis, 2016 update / D. Falzon, H.J. Schünemann, E. Harausz [et al.] // Eur. Respir. J. - 2017. - Vol.49(3).
Guglielmetti, L. Mycobacteria M-TMGot-FNRCf; the Physicians of the French MDRTBC. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? / L. Guglielmetti, Le Du D., N. Veziris [et al.] // Eur. Respir. J. - 2016. - Vol.48. - P.582–585.
Gunther, G. Treatment outcomes in multidrug-resistant tuberculosis / G. Gunther, C. Lange, S. Alexandru [et al.] // N. Engl. J. Med. - 2016. - Vol.375. - P.1103–1105.
Heyckendorf, J. Getting personal perspectives on individualized treatment duration in multidrugresistant and extensively drugresistant tuberculosis / J. Heyckendorf, I.D. Olaru, M. Ruhwald, C. Lange // Am. J. Respir. Crit. Care Med. - 2014. - Vol.190. - P. 374–383.
Karmakar, M. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE / M. Karmakar, C.H. Rodrigues, K.E. Holt [et al.] // PLoS One. - 2019. - Vol.14(5):e0217169.
Kaufmann, S.H. Progress in tuberculosis vaccine development and hostdirected therapies--a state of the art review / S.H. Kaufmann, C. Lange, M. Rao [et al.] // Lancet Respir. Med. - 2014. - Vol. 2. - P.301–320.
Kendall, E.A. Expected effects of adopting a 9-month regimen for multidrug-resistant tubercu-losis: a population modelling analysis / E.A. Kendall, A.T. Fojo, D.W. Dowdy // Lancet Respir. Med. - 2017. - Vol. 5. - P. 191–199.